FAPI Therapy

Fibroblast Activation Protein Inhibitor (FAPI) therapy, is a relatively new and emerging approach in cancer treatment. FAPI targets fibroblast activation protein (FAP), a protein found in the tumour microenvironment. FAP is associated with tumour growth, invasion, and metastasis.

FAPI therapy is being explored for various solid tumours, including pancreatic cancer, colorectal cancer, and others where FAP expression is prominent.

Potential Benefits

• Precision targeting and personalized treatment
• Improved quality of life
• Minimal damage to surrounding healthy tissues
• Serves both as a diagnostic and therapeutic agent.

How does it work?

• FAPI therapy involves the use of a radiolabeled compound that binds to FAP- expressing cells. FAPI ligands are not only used for therapy but also for imaging. FAPI agents, such as Gallium 68 for imaging and Lutetium-177 for treatment, are positioned to revolutionize the field of cancer care.
• Before treatment, diagnostic imaging using FAPI tracers helps identify FAP-expressing tumours and assess their extent.
• In contrast to conventional PET tracers like FDG, which gather in regions with elevated glucose metabolism, Gallium-68 FAPI selectively attaches to fibroblast activation proteins, improving the precision of tumour identification and staging.
• During treatment, the radiation emitted by the compound helps destroy these cells.